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Abstract
Background: Recent studies have shown that early antiretroviral therapy (ART) initiation results in significant HIV
transmission reduction. This is the rationale behind the “test and treat” policy of the World Health Organization
(WHO). Implementation of this policy will lead to an increased incidence of ART-related adverse effects, especially in
sub-Saharan Africa (SSA). Is the region yet ready to cope with such a challenging issue?
Main body: The introduction and widespread use of ART have drastically changed the natural history of HIV/AIDS,
but exposure to ART leads to serious medication-related adverse effects mainly explained by mitochondrial
toxicities, and the situation will get worse in the near future. Indeed, ART is associated with an increased risk of
developing cardiovascular disease, lipodystrophy, prediabetes and overt diabetes, insulin resistance and
hyperlactatemia/lactic acidosis. The prevalence of these disorders is already high in SSA, and the situation will be
exacerbated by the implementation of the new WHO recommendations. Most SSA countries are characterized by
(extreme) poverty, very weak health systems, inadequate and low quality of health services, inaccessibility to
existing health facilities, lack of (qualified) health personnel, lack of adequate equipment, inaccessibility and
unaffordability of medicines, and heavy workload in a context of a double burden of disease. Additionally, there is
dearth of data on the incidence and predictive factors of ART-related adverse effects in SSA, to anticipate on
strategies that should be put in place to prevent the occurrence of these conditions or properly estimate the
upcoming burden and prepare an adequate response plan. These are required if we are to anticipate and
effectively prevent this upcoming burden.
Conclusion: While SSA would be the first region to experience the huge benefits of implementing the “test and
treat” policy of the WHO, the region is not yet prepared to manage the consequential increased burden of
ART-related toxic and metabolic complications. Urgent measures should be taken to fill the lacunae if SSA is not
to become over-burdened by the consequences of the “test and treat” policy.
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Background
According to the Joint United Nations Programme on
HIV/AIDS (UNAIDS) global estimates, 38.7 million
people were living with HIV in 2015, among whom 2.1
million became newly infected (including 150 000 chil-
dren) and 1.1 million died from AIDS-related illnesses
[1]. The HIV pandemic is to-date one of the most ser-
ious health threats the world has ever witnessed. Since
the beginning of the epidemic, around 78 million people
have become infected with HIV, and 35 million people
have died from related complications [1]. For the specific
case of sub-Saharan Africa (SSA), 6.5 to 19 million
people were living with HIV in the region, with 410 000
to 960 000 new infections and 330 000 to 470 000
related deaths in 2015 [1].
Fortunately, the introduction and widespread use of
highly active antiretroviral therapy (ART) have drastic-
ally changed the natural history of HIV/AIDS. Indeed,
the longevity, prognosis and quality of life of people
living with HIV/AIDS (PLWHA) have significantly
improved over time. For instance, AIDS-related deaths
have decreased by 45% between 2005 and 2015 [1]. Initi-
ation of ART was initially based on the World Health
Organization (WHO) clinical stages or CD4 cell count
[2, 3]. But, these guidelines have recently been revised,
following conclusive reports from randomized controlled
trials which have shown a substantial benefit of early
ART initiation with significant reduction in HIV trans-
mission [4–6]. Based on these studies, the UNAIDS has
set out an ambitious target for 2020. By this year, they
would like 90% of people living with HIV to know their
status, 90% of all people with diagnosed HIV infection
to receive sustained ART, and 90% of all people receiving
ART to have viral suppression [7]. In order to achieve
this target, the WHO recommendations changed to a
“test and treat” policy advocating that ART should be
immediately started in all individuals diagnosed with
HIV regardless of age or CD4 cell count [8].
By the end of 2015, almost 17 million people were
already accessing ART globally and as a result of the pol-
icy shift to “test and treat”, an exponential increase in
the number of people receiving ART can thus be ex-
pected in the near future [1]. However, continuous ART
may lead to serious adverse effects mainly explained by
mitochondrial toxicities. These include: lactic acidosis,
pancreatitis, lipodystrophy, dyslipidaemias, insulin resist-
ance and dysglycemias [9–16]. Accordingly, it can be an-
ticipated that the burden of ART-related complications
(both toxic and metabolic) will increase in the near
future, especially in SSA which is the epicenter of the
HIV pandemic globally. This gives rise to the important
question of whether the region is sufficiently equipped
and prepared to manage this impending burden. The
present paper discusses the readiness of SSA countries
in implementing the “test and treat/90-90-90” policies
with regard to the upcoming increased burden of ART-
mediated toxic and metabolic complications.
Snapshot of challenges to implement the “test and treat/
90-90-90” policies in Africa
Each “90” target is subjected to difficulties in its imple-
mentation in SSA. For the first “90”: 90% of all people
living with HIV should know their HIV status, one can
include without limitation, lack of HIV testing proposals
by healthcare providers and low acceptance for HIV test-
ing by people [17]. Actually, it is recognized that only
20% of PLWHA in SSA know their HIV seropositive sta-
tus [18]. One of the greatest challenges in Africa would
be to implement easily accessible HIV counselling and
voluntary HIV testing. This is due to limited financial re-
sources, medical supplies, and weak health systems.
For the second “90”: 90% of people diagnosed with
HIV infection should receive sustained ART, difficulties
can include low rate of linkage to care, low rate of early
ART initiation after HIV seropositive screening, and
inadequate/insufficient stocks of ART to provide con-
tinuous medication to PLWHA [17, 19]. A study in SSA
showed for instance that only 12% of diagnosed-
PLWHA were linked to HIV/AIDS care after home-
based HIV counselling and testing [20].
For the third “90”: 90% of all people receiving ART
should have viral suppression, absence of proven
methods to ensure long time adherence to ART and re-
tention in care for all HIV-infected people, inadequate
stocks of ART, and weak early warning indicators for
HIV drug resistance can negatively impact this objective
in Africa [17, 21–25]. One can also include as transver-
sal impediments, lack of required financial resources for
HIV programs and limited supportive health system
infrastructures in resource-constrained settings.
Snapshot of the current burden of medication-related ad-
verse effects of continuous ART in SSA
There is growing evidence of a significant rise in cardio-
vascular disease (CVD) occurrence in PLWHA, more so
to those ART-exposed [26]. Studies in SSA signal to an
increased incidence of hypertension, diabetes mellitus
(DM), renal disease and stroke among ART-naïve
PLWHA as well as those on continuous ART [27–34].
Moreover, lipid disorders are very common in this popu-
lation: the overall prevalence of metabolic syndrome
turns around 8.7–58% in Africa [14, 35, 36]. Other stud-
ies have specifically identified other known CVD risk
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factors: higher low-density lipoproteins levels, lower
high-density lipoproteins levels, and higher apolipopro-
tein B/apolipoprotein A ratio [11, 27].
In addition, ART has been implicated as a risk factor for
developing prediabetes and overt diabetes mellitus [37]. In
some parts of SSA, the prevalence of dysglycemias is
almost 40% in ART-exposed PLWHA [12, 15, 38]. More
studies are needed to correctly estimate this risk of CVD
and metabolic syndrome, and identify factors that can
predict their development.
The prevalence of lipodystrophy in Africa reaches
69.9% and the incidence, 41.6% among PLWHA exposed
to ART [16], especially nucleoside analogue reverse tran-
scriptase inhibitors (NRTI)-containing regimen [10].
Lipodystrophy is known to be associated with older age
and longer duration on therapy, and has been linked
with a decreased quality of life, alterations in lipid, glu-
cose and insulin metabolisms, and an increased risk of
DM and CVD [16, 39].
Due to their ability to inhibit polymerase-γ, NRTIs are
associated with several mitochondrial toxicities, including
life-threatening lactic acidosis. The prevalence of hyper-
lactatemia is very high in SSA, varying between 17.1 and
83.2% among PLWHA on ART. Once symptomatic,
hyperlactatemia is associated with weakness, skin rashes,
tachypnea, and can lead to death [9, 13, 40–42]. However,
we recognize that this prevalence could be lower, consid-
ering that the new first line ART recommended by the
WHO does include ART with a lower toxicity profile than
previous regimen (removing stavudine for example).
Readiness of SSA countries to implement the new policies
of the WHO and UNAIDS: myth or reality?
Countries of the SSA region are resource-poor settings
with very weak health systems and poor quality of health
services [43–45], especially in the respect of implement-
ing the ‘test and treat’/90-90-90 policies [17, 19]. Health
facilities are not found everywhere, particularly in re-
mote and underserved rural areas. When these health
centres do exist, they are not always accessible due to
non-existent or unpassable roads. There is a crucial lack
of (qualified) health care personnel, with some areas not
having seen even a nurse. Under these circumstances,
who will test the population for HIV and follow-up those
found infected? Where are they going to be followed-up,
given the insufficient number of health facilities and
personnel? With 60% of the African population living in
rural areas and considering the extreme shortage of
health facilities and professionals in rural Africa, there is
urgent need to address these gaps with the regard of the
“test and treat” implementation in SSA. In addition to
the current shortfall of personnel and facilities necessary
to the full implementation of the 90-90-90 policy, and
with the expected increase in metabolic disorders
secondary to longer ART durations, there is a great need
for equipment, and more importantly, adequate numbers
of suitably qualified physicians and nurses to closely
monitor PLWHA. But these are not currently available.
For instance, CVD and DM remain poorly investigated
and managed in SSA [46–49]. Moreover, SSA countries
are still beset with infectious diseases which continue to
exact a heavy tool of illness and death in the region [50].
What’s worse, non-communicable diseases are becoming
common in these countries, leading thus to the double
burden of disease [50]. With the projected increase in
adverse events following initiation of ART in all
PLWHA, the current personnel, facilities, equipment,
and funding shortfalls will be greatly exacerbated in SSA
if some key measures are not implemented.
To date, there are no clear estimates on the incidence
of and risk factors for metabolic complications of ART
among HIV-infected people living in SSA, children
specifically [37, 39]. Therefore, it is difficult to predict
what proportion of PLWHA in SSA will develop ART-
related adverse effects and develop adequate action plans
to counter them. Since the risk factors for developing
these adverse effects are not known, measures to prevent
them cannot be formulated. Additionally, there is no
clear evidence on measures that might prevent PLWHA
on long-term continuous ART from developing ART-
related adverse effects, this by acting on identified risk
factors. Studies are therefore urgently required to fill
these gaps and help in designing effective strategies to
curtail the expected increase in ART-related adverse
effects in SSA following adoption of the new HIV/AIDS
recommendations.
Notwithstanding these fears, evidence suggests that
WHO/UNAIDS goals may be achievable in some SSA
nations. The SEARCH study was conducted in 32 commu-
nities in Uganda and Kenya and a total of 334 540 people
were enrolled. Participants were randomized to either re-
ceive standard HIV services or an expanded testing and
treatment program. Preliminary results show that 90% of
adults accepted the offer of testing, 93% of those diagnosed
with HIV stayed in medical care for at least 6 months, and
92% of those in care had a fully suppressed viral load [51].
Likewise, preliminary results from the PopART study which
involved 21 communities in South Africa and Zambia with
a cumulative population of 1.2 million people revealed that
an estimated 87% of women and 79% of men with HIV
knew their status, but just 65 and 62% of diagnosed men
and women respectively went on therapy. These numbers
are steadily increasing as the study continues [51, 52]. How-
ever, the prevalence and incidence of ART-related adverse
effects were not looked into in these studies. Also, the
researchers have been silent on strategies to identify and
handle these complications. The development of evidence-
based policy is urgently needed in this regard.
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Conclusion
Although it is unequivocally clear that early ART initi-
ation in the course of HIV infection will be beneficial at
both the individual and population levels, SSA appears
not yet ready to cope with the requirements and conse-
quences of implementing the “test and treat” strategy in
an efficient manner. Lack of organized health systems,
health facilities and qualified workforce may jeopardize
attainment of the WHO/UNAIDS goals. Furthermore,
adequate equipment and medicines will need to be made
accessible and affordable for all those PLWHA who will
develop ART-related adverse effects. Technical and fi-
nancial aids will be required for SSA countries to de-
velop systems and capacities to fill their gaps and
strengthen their weaknesses. Studies are urgently war-
ranted to study the incidence of and risk factors for
ART-related complications. These will enable countries
in SSA to draw strategies to tackle them effectively.
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